SHSafy Hadiya

Safy Hadiya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Safy Hadiya has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nanoparticle-Based Vaccines: From Design and Immune Modulation to Clinical Translation

    by Nada M. Elfeky, Merna G. Khalaf, Noha G. Morsi, Heba A. Fathi, Safy Hadiya, Omnia H.M. Omar, Gihan Fetih, Sherif I. Kamel, Mahmoud Elbadry

    Vaccines are one of the most notable developments in modern medicine, and their role in combating and even eradicating diseases cannot be overlooked. Through an immunological cascade, vaccines produce an immunological memory response evident by memory cells and antibodies formation. Ever since the introduction of the first vaccine against smallpox, great efforts have been made to further improve vaccine efficacy, overcome limitations, and develop vaccines against emerging pathogens. The utilization of nanotechnology in vaccines has many benefits, as nanotechnology can address most of the limitations of traditional vaccines. Moreover, it has paved the path for the development of several vaccinations and is expected to continue contributing to future advancements. Nanoparticles have several types, with each type having its advantages and drawbacks. The physicochemical characteristics of these nanoparticles, namely particle size, particle shape, particle rigidity, surface charge, and hydrophobicity, affect the immune response potency. Optimization of these properties can allow the manufacture of vaccines that trigger strong immune responses. This strategic optimization permitted the production of effective vaccine formulations against several major pathogens in the market. Notable nanoparticle vaccines include the human papillomavirus, malaria, hepatitis B, and severe acute respiratory syndrome coronavirus 2 vaccines. This comprehensive review explores the vaccine immunological cascade, the platforms of nanoparticles, their advantages and drawbacks, and the impact of their physicochemical characteristics on vaccine efficacy. Moreover, this review highlights the nanovaccine formulations that have been approved for use.

  • Nano-Ciprofloxacin/Meropenem Exhibit Bactericidal Activity Against Gram-Negative Bacteria and Rescue Septic Rat Model

    by Safy Hadiya, Reham A Ibrahem, Rehab M Abd El-Baky, Mahmoud Elsabahy, Abeer Mr Hussein, Mohammed Em Tolba, Sherine A Aly

    Aim: We hypothesized that simultaneous administration of two antibiotics loaded into a nanopolymer matrix would augment their synergistic bactericidal interaction. Methods: Nanoplatforms of chitosa... Plain language summary Antibiotics are used to treat bacterial infections. However, the more they are used, the less effective they become, because bacteria develop resistance to them. One strategy... Tweetable abstract CS/Plu-Cip/Mer resulting in a bactericidal effect versus the Cip/Mer bacteriostatic effect. The CS/Plu-Cip/Mer resulted in statistically significant reductions in all measures te... Graphical abstract Nano-Cip/Mer enhanced the survival rate and decreased the bacterial load in a septic rat model.


  • Levofloxacin-Loaded Nanoparticles Decrease Emergence of Fluoroquinolone Resistance in Escherichia coli

    by Safy Hadiya, Xiaoqiang Liu, Wegdan Abd El-Hammed, Mahmoud Elsabahy, Sherine A. Aly

    Antimicrobial resistance is a major global health problem that is developed upon exposure of bacteria to antimicrobial agents, and, thus, reducing or eliminating the ability of the currently available antibacterial drugs to eradicate bacterial infections. The aim of the current study was to encapsulate levofloxacin (third generation fluoroquinolones) into chitosan (CS) nanoparticles, to evaluate the antibacterial potency of the nanosized drug, and to characterize the major genetic mutations associated with the exposure of bacteria to the levofloxacin-loaded nanoparticle versus free levofloxacin. Three consecutive mutants were selected by stepwise exposure of one reference and two clinical Escherichia coli isolates to a series of progressively increasing concentrations of levofloxacin and the levofloxacin-loaded nanoparticles. Mutations in quinolone resistance determining region (QRDR) of gyrA and parC and regulators of AcrAB efflux pump ( soxR , soxS and acrR ) for all the selected-mutants were determined using polymerase chain reaction and sequencing. Mutants developed upon exposure to the nanosized drug had higher sensitivity to levofloxacin, compared with the levofloxacin-selected mutants. In addition, mutations in gyrA were observed in the levofloxacin first mutants, but in the nanosized levofloxacin second mutants. In the third mutants, an additional mutation in parC and mutations in the regulators were found only in levofloxacin-selected mutants. Loading of levofloxacin into the CS nanoparticles could increase the antibacterial activity of the drug and decrease the emergence of resistant mutants. To the best of our knowledge, this is the first study to explore the role of antimicrobial-loaded nanoparticles in the reduction of emergence of bacterial resistance.